Teardrop Cells Without Anemia: Diagnostic Significance
The presence of teardrop cells (dacrocytes) in the absence of anemia should prompt immediate evaluation for prefibrotic primary myelofibrosis (PMF), myelodysplastic syndrome (MDS), or early myeloproliferative neoplasm, as these cells indicate underlying bone marrow pathology even when hemoglobin levels remain normal.
Primary Diagnostic Considerations
Prefibrotic Primary Myelofibrosis (Most Critical)
The WHO criteria explicitly recognize that PMF can present without anemia and with minimal or no dacrocytes in early stages 1. In prefibrotic PMF:
- Dacrocytes may be "few if any" initially 1
- Anemia is listed as only a minor criterion (not required for diagnosis) 1
- The cardinal features are megakaryocyte proliferation with atypia and granulocytic proliferation 1
- Reticulin fibrosis is not required for diagnosis 1
Critical action: Obtain bone marrow biopsy to evaluate for megakaryocyte clustering, abnormally lobulated megakaryocytic nuclei, hypercellularity, and granulocytic proliferation. Test for JAK2V617F or MPL mutations 1.
Myelodysplastic Syndrome
The 2008 WHO revision expanded MDS categories to include patients with refractory cytopenia without anemia 2. Specifically:
- Refractory neutropenia (RN) or refractory thrombocytopenia (RT) can occur with unilineage dysplasia
- Patients may have bicytopenia without anemia
- Dysplastic changes can manifest morphologically before hemoglobin drops
Look for: Neutropenia, thrombocytopenia, pseudo-Pelger-Huët anomaly, dysgranulopoietic changes, macrocytosis, or monocytosis 1. Obtain bone marrow examination with cytogenetics.
Alternative Etiologies (Less Likely Without Anemia)
Hemolytic Processes
While dacrocytes are common in autoimmune hemolytic anemia (AIHA) and microangiopathic hemolytic anemia (MAHA) 3, 4, these conditions virtually always present with anemia. The absence of anemia makes active hemolysis unlikely unless:
- Compensated hemolysis with robust reticulocytosis (check reticulocyte count, LDH, haptoglobin, bilirubin)
- Very early presentation
Dacrocytes in hemolytic anemia are associated with splenomegaly and extramedullary hematopoiesis 4, which should be clinically apparent.
Diagnostic Algorithm
- Complete blood count with differential: Assess for thrombocytosis, leukocytosis, neutropenia, or thrombocytopenia
- Peripheral smear review: Quantify dacrocytes, evaluate for leukoerythroblastosis, dysplastic features, or immature cells
- Spleen assessment: Physical exam and imaging for splenomegaly
- Laboratory markers: LDH, uric acid (elevated in myeloproliferative disorders)
- Molecular testing: JAK2V617F, CALR, MPL mutations
- Bone marrow biopsy with reticulin stain: Essential to diagnose prefibrotic PMF or MDS
- Cytogenetic analysis: MDS-associated abnormalities (del 5q, del 20q, trisomy 8)
Critical Pitfalls to Avoid
- Do not dismiss dacrocytes as insignificant simply because anemia is absent—they indicate bone marrow pathology requiring investigation
- Do not wait for anemia to develop before pursuing bone marrow evaluation if other features suggest myeloid neoplasm
- Do not attribute dacrocytes to hemolysis without confirming active hemolysis through reticulocyte count and hemolytic markers
- Do not overlook subtle cytopenias in other cell lines that may indicate early MDS or PMF
Clinical Context
The presence of dacrocytes represents altered erythropoiesis or splenic remodeling of red cells. In the absence of anemia, this morphologic finding most commonly signals:
- Early myeloproliferative neoplasm where proliferative features dominate over cytopenias
- Prefibrotic myelofibrosis where bone marrow architecture is beginning to change
- MDS with preserved erythropoiesis but dysplasia in other lineages
The finding demands bone marrow evaluation to exclude clonal myeloid disorders that require monitoring and may progress to overt myelofibrosis, acute leukemia, or symptomatic cytopenias.